Ask AI
ProCE Banner Activity

Integrating HER2-Directed ADCs Across Early and Metastatic Breast Cancer: Practical Strategies for Testing, Sequencing, and Patient-Centered Care

Slideset

Download these slides to enhance your ability to integrate key findings from clinical trials on HER2-directed ADCs across early-stage and metastatic breast cancer to individualize treatment plans.

Released: May 29, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Target Audience

This activity is intended for oncologists, advanced practice providers, pharmacists, nurse practitioners, clinical nurse specialists, nurses, and other healthcare professionals who care for patients with breast cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Apply current evidence and guideline principles to select and sequence HER2-directed therapies across early-stage and metastatic breast cancer 

  • Interpret evolving data on HER2-directed ADCs and integrate key findings into individualized treatment planning for patients with HER2-positive and HER2-expressing disease

  • Improve accuracy in ordering, interpreting, and communicating HER2 IHC and ISH results, including differentiation of HER2-positive, HER2-low, and HER2-ultralow categories, and determine when repeat testing is clinically appropriate

  • Identify early indicators of treatment-related events associated with HER2-directed therapies and coordinate multidisciplinary approaches to monitoring, evaluation, and supportive care

  • Incorporate real-world considerations such as CNS involvement, comorbidities, treatment tolerability, and patient preferences into evidence-based therapeutic decision-making

  • Recognize appropriate candidates for clinical trials and employ patient-centered communication strategies to support equitable access to emerging therapies